本帖最后由 老马 于 2012-1-13 21:20 编辑 ' j' y7 Z# h C/ P" c: L! A% h! f
* |6 C) n# @2 J, t7 ?8 `' i/ o& t
爱必妥和阿瓦斯丁的比较; P, A1 H3 }; X2 B7 ~2 b1 y
* I) b* S: j, H, u# |3 j) rhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
2 a6 `5 R% V# d: s4 x) Y n
# _8 [. D E2 P/ h" R' w
5 o* M# Y- K3 l
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/# Q$ ]1 d: x/ G( {7 K7 V4 B
==================================================
( a8 L. X/ |6 C; LOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)5 A% }7 ~6 h: |9 l }# u" O
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
, _9 e( e+ }* [; Q( R" tResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.2 f( _$ f+ W8 k- M1 d/ d A4 ^
|